Natural killer (NK) cell responses in primates are regulated in part through interactions between two highly polymorphic molecules, the killer-cell immunoglobulin-like receptors (KIRs) on NK cells and their major histocompatibility complex (MHC) class I ligands on target cells. We previously reported that the binding of a common MHC class I molecule in the rhesus macaque, Mamu-A1*002, to the inhibitory receptor Mamu-KIR3DL05 is stabilized by certain simian immunodeficiency virus (SIV) peptides, but not by others. Here we investigated the functional implications of these interactions by testing SIV peptides bound by Mamu-A1*002 for the ability to modulate Mamu-KIR3DL05 + NK cell responses. 
eight of 75 SIV peptides bound by Mamu-A1*002 suppressed the cytolytic activity of primary Mamu-KIR3DL05 + NK cells, including three immunodominant CD8 + T cell epitopes previously shown to stabilize Mamu-A1*002 tetramer binding to Mamu-KIR3DL05. Substitutions at C-terminal positions changed inhibitory peptides into disinhibitory peptides, and vice versa, without altering binding to Mamu-A1*002. The functional effects of these peptide variants on NK cell responses also corresponded to their effects on Mamu-A1*002 tetramer binding to Mamu-KIR3DL05. In assays with mixtures of inhibitory and disinhibitory peptides, low concentrations of inhibitory peptides dominated to suppress NK cell responses. 
Introduction
By virtue of their ability to recognize and kill infected cells without prior exposure to antigen, natural killer (NK) cells provide an important innate defense against viral pathogens. NK cells differentiate virus-infected cells from healthy cells through the integration of complex signals from activating and inhibitory receptors, which in primates include the highly polymorphic killer-cell immunoglobulin-like receptors (KIRs). Whereas the molecular basis of ligand recognition for the activating KIRs is not fully understood, inhibitory KIRs selectively bind to subsets of major histocompatibility complex (MHC) class I molecules bearing particular sequence motifs in their α1-domains [1] [2] [3] . Inhibitory KIRs normally suppress NK cell activation through interactions with their MHC class I ligands on the surface of healthy cells. However, when these interactions are perturbed, for instance as a result of MHC class I downregulation by the human immunodeficiency virus (HIV)-1 Nef protein [4] [5] [6] , this inhibition is lost resulting in NK cell degranulation and lysis of the infected cell. Polymorphic differences in KIR and HLA class I genes can influence the course of HIV-1 infection [7] [8] [9] [10] [11] [12] , as well as the outcome of infection with other viral pathogens, including hepatitis C virus (HCV) [13] , human papillomavirus (HPV) [14] and cytomegalovirus (CMV) [15] . In the case of HIV-1, activating and highly-expressed inhibitory alleles of KIR3DL1/S1, in combination with HLA-Bw4 alleles encoding isoleucine at position 80 (HLA-Bw4-80I), are associated with delayed progression to AIDS and greater suppression of viral replication in autologous CD4 + T cells by bulk NK cells [8, 9, 16] . In accordance with these genetic associations, NK cells expressing KIR3DS1 can suppress the in vitro replication of HIV-1 in HLA-Bw4-80I + lymphocytes [17] , and KIR3DS1 + and KIR3DL1 + NK cells preferentially expand during HIV-1 infection in HLA-Bw4-80I + individuals [18] . KIR-expressing NK cells may also exert selective pressure on virus replication as demonstrated by HIV-1 polymorphisms associated with KIR2DL2 that confer resistance to NK cells expressing this KIR [19] . Consistent with three-dimensional structures of KIR-HLA class I complexes revealing that KIRs contact surfaces of their HLA class I ligands over C-terminal residues of the bound peptide [20] [21] [22] , changes in C-terminal positions of the peptide can stabilize or disrupt interactions with inhibitory KIRs [23] [24] [25] [26] . NK cells may therefore sense changes in the repertoire of peptides presented by the MHC class I ligands of inhibitory KIRs. Although this helps to explain how NK cells differentiate virus-infected cells from healthy cells, it also creates an opportunity for immune escape. By acquiring changes in epitopes that enhance MHC class I binding to inhibitory KIRs, viruses may prevent the elimination of infected cells by NK cells. Indeed, such a mechanism may account for the adaptation of HIV-1 for resistance to KIR2DL2 + NK cells [19] .
We previously demonstrated that the binding of Mamu-A1 Ã 002, a common MHC class I molecule in the rhesus macaque, to Mamu-KIR3DL05 is stabilized by certain simian immunodeficiency virus (SIV) peptides, but not by others [27] . We previously reported that Mamu-A1 Ã 002 tetramers folded with some SIV peptides, but not others, bind to Mamu-KIR3DL05 [27] . To evaluate the functional implications of these interactions, we tested individual peptides for the ability to inhibit NK cell degranulation in cytotoxicity assays. Primary NK cells were expanded from rhesus macaque peripheral blood mononuclear cells (PBMCs) by stimulation with γ-irradiated K562 Clone9.mbIL21 cells [28] and sorted into Mamu-KIR3DL05 + and -KIR3DL05 -subsets using Mamu-A1 Ã 002 Gag GY9
tetramers. These NK cells were then tested in cytoxicity assays for recognition of a Mamu-A1 Ã 002-expressing, transporter associated with antigen processing (TAP)-deficient 721.221 cell line (721.221-ICP47-A1 Ã 002) incubated with specific SIV peptides. Because TAP is necessary for the translocation of peptides from the cytoplasm into the endoplasmic reticulum, MHC class I molecules expressed in these cells cannot load peptides derived from endogenously synthesized proteins, and are rapidly internalized from the plasma membrane [29, 30] . (Fig 1A) . The same pattern of peptide-dependent inhibition was reproducible with Mamu-KIR3DL05 + NK cells from four different animals (Fig 1B) , and was not the (Fig 2) . Ordered from highest to lowest binding affinity for Mamu-A1 Ã 002, these inhibitory peptides include seven previously defined CD8 + T cell epitopes known to be presented on the surface of SIV-infected cells [31] . Notably, the four peptides with highest affinity for Mamu-A1 Ã 002, including three immunodominant CD8 + T cell epitopes (Nef YY9, Env RY8, and Gag GY9; purple), strongly suppressed the cytolytic activity of Mamu-KIR3DL05 + NK cells (Fig 2) . Because of their high affinity for Mamu-A1 Ã 002, (Fig 3) . In the case of Gag GY9, alanine or tryptophan substitutions at position 8 partially (GY9 L8A), or completely (GY9 L8W), abrogated Mamu-KIR3DL05 + NK cell inhibition (Fig 3A and 3B) . Similar results were obtained for GY9 variants with tyrosine or phenylalanine at this position (S4 Fig), suggesting that the presence of a bulky aromatic side chain at position 8 may interfere with Mamu-A1 Ã 002 binding to Mamu-KIR3DL05. In the case of Nef YY9, opposite effects were observed for alanine versus + NK cells. Mamu-KIR3DL05 + NK cells were incubated at a 5:1 E:T ratio with CAM-labeled 721.221-ICP47-A1*002 target cells pulsed with the indicated SIVmac239 peptides. Percent specific lysis was calculated from the amount of CAM released into the culture supernatant after a 4-hour incubation. Bars represent the mean percent specific lysis for experiments using NK cells from three different animals. Peptides are ordered from highest to lowest affinity for Mamu-A1*002 according to Loffredo et al. [31] . Previously defined CD8 + T cell epitopes are indicated by purple bars and controls include target cells incubated without peptide (blue) or with a GY9 variant with substitutions at anchor positions that abrogate binding to Mamu-A1*002 (red). Error bars indicate +1 SD and asterisks indicate significant differences in the lysis of target cells pulsed with each SIV peptide compared to control cells without peptide (*p<0.05, **p<0.01, ***p<0.005, ****p<0.001 by one-way ANOVA with Dunnett's test). Stabilization of Mamu-A1*002 on the surface of 721.221-ICP47-A1*002 cells was verified by flow cytometry using the MHC class I-specific monoclonal antibody W6/32 (S1 Fig). doi:10.1371/journal.ppat.1005145.g002 tryptophan substitutions at position 8. Whereas replacement of arginine with alanine (YY9 R8A) further suppressed the cytolytic activity of Mamu-KIR3DL05 + NK cells compared to the wild-type peptide, a tryptophan substitution (YY9 R8W) allowed killing to a similar extent as the control peptide that does not bind to Mamu-A1 Ã 002 (Fig 3C and 3D ). Substitutions at positions 6 and 7 also resulted in partial (YY9 G6A and G6W), or a nearly complete (YY9 I7W), loss of inhibition, suggesting that these residues may also contribute to interactions with Mamu-KIR3DL05. Similar to Gag GY9 and Nef YY9, a valine-to-tryptophan substitution in the penultimate position of Env RY8, in this case position 7 (RY8 V7W), completely abrogated inhibition (Fig 3E and 3F) . A significant increase in cytolyic activity was also observed for a tryptophan substitution at position 6 (RY8 R6W) (Fig 3E and 3F ). Yet neither alanine nor tryptophan substitutions at position 5 had a detectable effect on Mamu-KIR3DL05 + NK cell responses to any of these peptides (Fig 3A-3F ). In the case of Vif IW9, single amino acid substitutions were not sufficient to change this disinhibitory peptide into an inhibitory variant. However, a combination of substitutions at positions 8 and 9 (IW9 F8A W9Y) resulted in significant inhibition of Mamu-KIR3DL05 + NK cells (Fig 3G and 3H ), demonstrating that it is also possible to convert a peptide that permits a cytolytic response into one that suppresses this activity with only a couple of amino acid changes. Taken together, these results reveal a prominent role for residues at the penultimate position of Mamu-A1 Ã 002-bound peptides, with additional contributions of the two preceding residues, in modulating Mamu-A1 Ã 002 interactions with Mamu-KIR3DL05.
To confirm that these functional differences in NK cell responses reflect the effects of Mamu-A1
Ã 002-bound peptides on molecular interactions with Mamu-KIR3DL05, custom
Mamu-A1 Ã 002 tetramers were synthesized with selected Gag GY9 and Nef YY9 variants and tested for their ability to bind to Mamu-KIR3DL05. Jurkat cells were electroporated with a plasmid DNA construct that expresses HA-tagged Mamu-KIR3DL05 and then stained with tetramer and an HA-specific monoclonal antibody (Fig 4A) , as previously described [27] . The integrity of each of the tetramers was also verified by staining a cell line that stably expresses LILRB1, which binds to MHC class I molecules folded with β2-microglobulin independently of MHC-bound peptide (Fig 4B) (Fig 4A) . Conversely, the Nef YY9 R8A variant, which enhances Mamu-KIR3DL05 + NK cell inhibition (Fig 3C and 3D) , increases Mamu-A1 Ã 002 binding to Mamu-KIR3DL05 compared to the wild-type Nef YY9 peptide (shifts tetramer staining to slightly lower surface levels of Mamu-KIR3DL05/HA) ( Fig 4A) . Furthermore, the Gag GY9 L8W and Nef YY9 R8W variants, which allow full cytolytic activation of Mamu-KIR3DL05 + NK cells (Fig 3A-3D) , completely abrogate Mamu-A1 Ã 002 binding to Mamu-KIR3DL05 ( Fig 4A) . These tryptophan substitutions do not interfere with the folding of Mamu-A1 Ã 002-peptide complexes, since Gag GY9 L8W and Nef YY9 R8W tetramers retain the ability to bind to LILRB1 (Fig 4B) . Thus, the functional effects of amino acid changes at position 8 of Gag GY9 and Nef YY9 on Mamu-KIR3DL05 + NK cell responses correspond to their effects on Mamu-A1 Ã 002 binding to Mamu-KIR3DL05.
Structural modeling of amino acid replacements in SIV peptides bound by Mamu-A1*002
Three-dimensional crystal structures of Mamu-A1 Ã 002 in complex with Gag GY9 and Nef YY9 reveal how changes in C-terminal positions of these peptides may affect interactions with Mamu-KIR3DL05 [35, 36] . These structures show that the side chains of the residues at position 8 of both peptides project over the α1-domain of Mamu-A1 Ã 002 in an orientation to interact with Mamu-KIR3DL05 [35, 36] . In the case of Gag GY9 L8A, the methyl group of the alanine at this position should not interfere with Mamu-A1 Ã 002 binding to Mamu-KIR3DL05
( Fig 5A) . However, this side chain is also unlikely to contribute to the stability of the interaction to the same extent as the longer aliphatic side chain of leucine, which probably explains the decrease in tetramer binding (Fig 4A) and the partial increase in cytolytic activity for this peptide (Fig 3A) . In the case of Gag GY9 L8W, the bulky indole ring of tryptophan at position 8 projects out of the peptide-binding pocket in an orientation to directly interfere with binding to Mamu-KIR3DL05. Indeed, Mamu-A1 Ã 002 tetramer folded with this peptide failed to bind to Mamu-KIR3DL05 under conditions of protein over-expression in transfected cells (Fig 4A) . Disruption of Mamu-KIR3DL05 binding to Mamu-A1 Ã 002 therefore explains the complete loss of NK cell inhibition and the strong cytolytic response against 721.221-ICP47-A1 Ã 002 cells pulsed with this peptide (Fig 3A) . Similar modeling of Nef YY9 I7W and R8W in complex with Mamu-A1 Ã 002 reveals that the ring structures at positions 7 and 8 of these peptides protrude from the peptide-binding pocket (Fig 5B) . Hence, these tryptophan substitutions may also hinder Mamu-KIR3DL05 binding to Mamu-A1 Ã 002, accounting for the lack of Mamu-A1 Ã 002-YY9 R8W tetramer binding to Mamu-KIR3DL05 (Fig 4A) and the robust cytolytic activity against cells pulsed with each of these peptide variants (Fig 3C) . Inhibitory peptides dominate over variants that do not suppress NK cell responses MHC class I molecules present a diverse repertoire of peptides derived from viral and cellular antigens on the surface of virus-infected cells, of which some may stabilize and some may disrupt interactions with any given KIR. We therefore asked which signal dominates when a mixture of peptides that do or do not suppress NK cell activity is presented on the cell surface. [35, 36] . The α1-and α2-domains of the MHC class I heavy chain (blue), β2-microglobulin (grey), and SIV peptide (yellow) are depicted. (Fig 6A-6D) . To determine the threshold at which the inhibitory effects of these peptides are observed, increasing concentrations of Gag GY9 and Env RY8 were tested in the presence of a fixed, sub-saturating concentration of Gag GY9 L8W and Env RY8 V7W. Half-maximal inhibition of killing was achieved at approximately 5% of the total peptide concentration for both Gag GY9 and Env RY8 (Fig 6E and 6F) 
Discussion
Genetic studies have associated certain combinations of KIR and HLA class I alleles with the control of HIV, HPV, and HCV infections, suggesting that KIR-MHC class I interactions play an important role in the immune response to these viruses [8, 9, 13, 14] . However, less is known about whether viral peptides affect the interaction of KIR with their ligands during infection, despite abundant evidence demonstrating that KIR recognition is influenced by MHC class Ibound peptides [24] [25] [26] [27] 32, 37] , including variants of some HIV peptides [38] [39] [40] . In panels A-D, the percentages of inhibitory versus disinhibitory peptides varied, keeping the total peptide concentration constant at 0.5 μM for GY9/ GY9 L8W and 5 μM for RY8/RY8 V7W. Error bars indicate +1 SD and asterisks indicate significant differences in the lysis of target cells pulsed with GY9 or RY8 compared to target cells pulsed with the indicated peptide mixtures (*p<0.05, ****p<0.001 by two-way ANOVA with Dunnett's test). In panels E-F, target cells were pulsed with increasing concentrations of Gag GY9 (E) or Env RY8 (F) in combination with a fixed concentration of their respective disinhibitory variants (0.375 μM GY9 L8W or 3.75 μM RY8 V7W). The dashed line indicates 50% inhibition where GY9 or RY8 alone defines 100% inhibition and GY9 L8W or RY8 V7W alone defines 0% inhibition. Mamu-A1*002 stabilization on the surface of 721.221-ICP47-A1*002 cells was verified by flow cytometry using the MHC class I-specific monoclonal antibody W6/32 (S5 Fig). doi dominate to suppress NK cell activation. When present at a concentration of just 5% of a mixture with their respective disinhibitory variants, Gag GY9 and Env RY8 exhibited approximately 50% of their maximal capacity to inhibit the lysis of Mamu-A1 Ã 002 + target cells. These observations are consistent with the need to prevent NK cell lysis of normal healthy cells presenting diverse self-peptides in complex with MHC class I ligands, and imply that for a viral peptide to cause NK cell degranulation by preventing engagement of an inhibitory KIR, it would need to be presented on the cell surface at a sufficiently high density to overcome negative signals from the same MHC class I ligand loaded with other peptides. In this respect, our results contrast with previous studies, which found that low concentrations of 'antagonistic' peptides were sufficient to overcome inhibition by peptides that stabilize HLA-Cw Ã 0102 binding to KIR2DL2 and KIR2DL3 [26, 43] . A possible explanation for the difference in our results may be the nature of the peptides examined. Whereas antagonistic peptides are distinguished by weak KIR binding that does not induce NK cell inhibition [26] , the peptide variants used in our assays contain tryptophan substitutions with bulky aromatic side chains predicted to abrogate KIR binding. Furthermore, because antagonism is less efficient for high avidity HLA-KIR interactions [26] , any antagonistic effects of our variants may have been overcome by the unusually high avidity of Mamu-A1 Ã 002-Gag GY9 and -Env RY8 complexes for Mamu-KIR3DL05 [27] . Alternatively, differences in our results may reflect fundamental differences in ligand recognition for KIRs with two versus three immunoglobulin-like domains. In the absence of a D0 domain to stabilize MHC class I binding, 2D KIRs may be more sensitive than 3D KIRs to MHC class I-bound peptides. In support of this possibility, changes at position 8 of HLA class I-bound peptides have been shown to have a more dramatic effect on the K d of HLA-Cw3 binding to KIR2DL2 than on that of HLA-B Ã 57 binding to KIR3DL1 [20, 21] .
While inhibitory peptide dominance is compatible with the need to prevent NK cell lysis of healthy cells, it also provides an avenue for viruses to gain resistance to NK cells by acquiring changes in epitopes that increase the binding of MHC class I ligands to inhibitory KIRs. Indeed, this may explain the selective pressure for HIV-1 to acquire polymorphisms that increase the binding of KIR2DL2 to virus-infected cells and impair virus suppression by NK cells from KIR2DL2 + individuals in vitro [19] . Therefore, it is perhaps not a coincidence that the four SIV peptides bound with the highest affinity by Mamu-A1 Ã 002, including three immunodominant CD8 + T cell epitopes known to be processed and presented on the surface of virus-infected cells (Nef YY9, Env RY8 and Gag GY9), all suppress Mamu-KIR3DL05 + NK cell responses. Although multiple factors determine the efficiency of MHC class I presentation, the high affinity of Mamu-A1 Ã 002 for these peptides suggests that they may be presented in abundance on the surface of SIV-infected cells expressing this MHC class I molecule. Given that Mamu-KIR3DL05 and -A1 Ã 002 are commonly expressed in Indian origin rhesus macaques [27] , it is therefore conceivable that SIV may have acquired changes in one or more of these epitopes to stabilize this KIR-MHC class I interaction as a mechanism of NK cell evasion. In accordance with this possibility, Mamu-KIR3DL05 + NK cells were less effective than Similar observations in humans suggest that NK cells exert selective pressure on HIV-1 replication in certain individuals. KIR2DL2-associated HIV-1 polymorphisms were identified in chronically infected individuals that increase the binding of this inhibitory KIR to virusinfected cells and impair the ability of NK cells from KIR2DL2 + individuals to suppress virus replication in vitro [19] . Although the HLA class I ligands and specific viral peptides associated with these polymorphisms were not identified, subsequent studies defined a few HIV-1 peptides that could enhance the binding of KIR2DL2 to two HLA-C1 allotypes [39, 40] . These observations are analogous to the identification of SIV peptides that inhibit Mamu-KIR3DL05 + NK cell responses. However, because rhesus macaques do not express KIR2D receptors of the D1-D2 configuration or their HLA-C ligands [44] [45] [46] [47] , the mechanisms of NK cell inhibition in humans and macaques may differ. Whereas HLA-C is not downregulated by HIV-1 Nef [5, 6] , Mamu-A1 Ã 002 is subject to downregulation by the SIV Nef protein [42] . Thus, it is conceivable that amino acid changes in HIV-1 epitopes that merely eliminate interference with HLA-C binding to KIR2DL2 would be sufficient to inhibit KIR2DL2 + NK cells, but substitutions in SIV epitopes that increase the stability of Mamu-KIR3DL05 binding to Mamu-A1 Ã 002 may be necessary to overcome incomplete downregulation of this ligand by Nef to adequately suppress KIR3DL05 + NK cells.
Although HLA class I-bound peptides also influence interactions with human KIR3DL1 [38, 41] , functional parallels with Mamu-KIR3DL05 are limited. Whereas Mamu-KIR3DL05 + NK cells exhibit impaired NK cell suppression of SIV replication in autologous Mamu-A1 Ã 002 + lymphocytes, human NK cells from individuals possessing highly-expressed alleles of KIR3DL1 are better able to suppress HIV-1 replication in autologous HLA-B Ã 57 + lymphocytes [16] . Moreover, unlike Mamu-KIR3DL05, which appears to be associated with elevated viral loads in SIV-infected animals [48] , certain highly expressed alleles of KIR3DL1, in combination with their HLA-Bw4 ligands, are associated with lower viral loads and slower progression to AIDS in HIV-1 infected individuals [9] . These contrary observations may reflect fundamental differences in the molecular interactions of Mamu-KIR3DL05 versus KIR3DL1 with their ligands, as these receptors represent highly divergent products of non-orthologous genes [27] . 
Materials and Methods

Ethics statement
The Indian origin rhesus macaques (Macaca mulatta) used in this study were housed and cared for in an indoor ABSL2+ facility at the New England Primate Research Center (NEPRC) in accordance with standards of the Association for Assessment and Accreditation of Laboratory Animal Care and the Harvard Medical School Animal Care and Use Committee. Animal experiments were approved by the Harvard Medical Area Standing Committee on Animals under protocol 04873 and conducted according to the principles described in the Guide for the Care and Use of Laboratory Animals [49] . Steps taken to improve animal welfare included social housing and environmental enrichment such as foraging opportunities and manipulable devices. Water was supplied ad libitum and animals were provided commercial monkey chow twice daily and fresh produce at least three times per week. Animals were monitored twice daily by animal care and veterinary staff, and suffering due to experimental procedures was minimized by sedation with ketamine HCl prior to blood collection.
Stable cell lines
To were placed under selection with 0.4 μg/mL puromycin, 500 μg/mL of G418, and 100 μg/mL of hygromycin additively after each transduction.
NK cell expansion and cell culture PBMC (5 × 10 6 cells) were stimulated with 1 × 10 7 γ-irradiated K562 Clone 9.mbIL21 cells [28] in a volume of 40 mL of NKEM: RPMI 1640 (Invitrogen) supplemented with 10% FBS (Invitrogen), glutamine (Invitrogen), Primocin (InvivoGen), and 50 U/mL IL-2 (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, contributed by Dr. Maurice Gately, Hoffmann-La Roche Inc.) [51] . On days 3 and 5 after culture, cells were resuspended in fresh medium. The expanded NK cells were re-stimulated on day 7, and weekly thereafter, with additional γ-irradiated K562 Clone 9.mbIL21 cells at a 1:1 ratio. From day 7 onward, expanded cells were resuspended in fresh medium at 4 × 10 5 cells/mL 2-3 times weekly.
NK cell sorting
Expanded NK cell cultures were incubated with anti-CD3 Ab (clone 6G12) and T cells were depleted using pan-mouse IgG Dynabeads (Dynal Biotech). Kollnberger, University of Oxford) were stained with each tetramer as previously described [32] . All data was acquired using a LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo 8.8.6.
Structural modeling
Molecular graphics and analyses were performed with the UCSF Chimera package developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311). Modeling of amino acid substitutions in the structures of Mamu-A1 Ã 002 in complex with GY9 (PDB 3JTS) [35] or YY9 (PDB 3JTT) [36] were carried out using the swapaa function in which rotamer position is determined by minimal clash score, maximal hydrogen bonding, and probability according to the Dunbrack rotamer library [52] .
Viral suppression assay
The target cells were prepared by depletion of CD8 + cells from PBMC by treatment with CD8-Dynabeads (Dynal Biotech) followed by ConA-activation (5 μg/ml) in RPMI 1640 supplemented with 10% FBS, glutamine, HEPES (Invitrogen), and Primocin (R10) for 4 days. On the day of the assay, 2 × 10 6 target cells were infected with 100 ng p27 SIV mac 239 in minimal volume for 3 hours at 37°C, then washed. Mamu-KIR3DL05 + and -KIR3DL05 -NK cell subsets were sorted as described above and were incubated with 2 × 10 4 SIV-infected autologous CD4 + target cells in R10 + 20 U/mL IL-2 in duplicate wells at a 5:1 or 3:1 E:T ratio. On days 3, 5, 7, and 9/10, 50 uL of supernatant was sampled with replacement. SIV titer was determined by SIV p27 Antigen Capture Assay (Advanced Bioscience Laboratories). Area under the curve was calculated using Prism 6 (GraphPad).
Luciferase lysis assay
Four days prior to the assay, 721.221-CD4-A1 Ã 002-LTRluc cells, which express luciferase when infected with SIV, were infected by spinoculation [53] in the presence of 4 μg/mL of Polybrene (Sigma-Aldrich). On the day of the assay, infected cells were washed three times and 
